Lyell Immunopharma, Inc. (LYEL) NASDAQ
14.89
-2.26(-13.18%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Lyell Immunopharma, Inc.
Address
201 Haskins Way
South San Francisco, CA 94080
United States of America (the)
Phone
650 695 0677
Website
Sector
Healthcare
Industry
Biotechnology
Employees
300
First IPO Date
June 17, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Lynn Seely | Principal Executive Officer, President, CEO & Director | 1.13M | 1959 |
| Richard D. Klausner | Founder & Executive Chairman | 85,000 | 1952 |
| Gary Lee | Chief Scientific Officer | 786,805 | 1977 |
| Stephen J. Hill | Chief Operating Officer | 830,564 | 1971 |
| Mark A. Meltz | General Counsel & Corporate Secretary | 0 | 1974 |
| Stanley R. Riddell | Founder & Scientific Advisor | 0 | N/A |
| Nellie Dillery | Director of Accounting | 0 | N/A |
| Jarrad Aguirre | Senior Vice President of Medical Affairs | 0 | N/A |
| Bryan Selby | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Ann Tomlin | Chief Human Resources Officer | 0 | N/A |
| Crystal L. Mackall | Founder & Scientific Advisor | 0 | 1961 |
| Smital Shah | Principal Financial Officer, CFO & Chief Business Officer | 0 | 1976 |
| Veronica Sanchez Bulis | VP, Corporate Controller, Principal Accounting Officer | 0 | 1978 |
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
